Kazakhstan Medical Device Registration Route Decision Model: Three Inputs, Four Outcomes

1. Key takeaways

Registration route decisions for Kazakhstan can be quantified with three inputs: market scope (Kazakhstan only, or including other EAEU member states), evidence maturity (whether acceptable foreign clinical data, an ISO 13485 certificate and a complete technical file already exist), and the time window (whether submission can be completed before December 31, 2027). The three inputs combine into four dispositions: national pathway first, union pathway first, dual-track parallel, and defer. The value of this model is not that it computes a single answer, but that it converts vague discussions of whether to enter Kazakhstan into an executable list of which models go first and on which track. Once the inputs are scored for every model in the portfolio, the debate shifts from strategy to sequencing, and the deadlines embedded in the protocol of December 29, 2025 become ordinary scheduling constraints rather than sources of uncertainty. The same scoring can be repeated each quarter at negligible cost, which keeps the plan aligned as evidence accumulates and market plans shift.

2. Legal basis

3. Expert insights

Insight one: market scope is the first filter and the only input that cannot be compromised. If the next three years cover Kazakhstan only, the extra cost of the union route’s reference-state and recognizing-state procedures cannot be spread over several markets; if two or more member states are in scope, the union route’s cost per market is clearly lower. A mistake on this input cannot be compensated by optimizing the other two, so it should be settled first, in writing, with the three-year regional plan rather than with the current order book. Where the regional plan is genuinely undecided, model both scenarios and treat the difference in cost as the price of flexibility.

Insight two: evidence maturity determines whether the window can be caught. The national route accepts existing foreign clinical data without repeating studies inside the union, so models that already hold EU or US clinical evidence and an ISO 13485 certificate move from project start to submission in a clearly shorter period than models that still need testing. With a limited window, evidence maturity effectively decides how many models fit inside it, and it should be scored per model rather than assumed for the portfolio as a whole.

Insight three: the time window is a hard constraint, and backward planning is the only correct method. Plan backward from December 31, 2027: testing schedules, sample shipping, bilingual documentation and site inspections each occupy a segment of the runway. The 2026 one-window combined service, with a total of no more than 100 working days (and an accelerated lane of as few as 15 working days), adds flexibility for projects inside the window, but remedy and inspection time must be added back manually rather than assumed away. Reserve the last months of the window for remedies rather than for the original submission, since late filings compete with a peak of parallel filings from other applicants.

Insight four: dual-track parallelism is not a compromise but an active choice with clear use cases. Mature models go through the national route to lock in long-term Kazakhstan access (registration certificates carry no expiry date), while newly developed models go through the union route to cover multiple countries; this is the most common effective combination. The genuine error to avoid is preparing two mutually contradictory dossiers for the same model on both tracks, which a unified version control mechanism prevents.

Insight five: the portfolio health check must output a ranking, not just a verdict. The value of reviewing the portfolio lies in the priority order of which models go first, not in answering whether to proceed at all. Rank the models by feasibility within the window multiplied by market value divided by compliance cost, and revisit the ranking whenever one of the three inputs changes materially. A ranking that is reviewed quarterly stays honest; one that is written once and filed away does not.

4. Practical recommendations

1. Score every model against the three inputs and output one of the four dispositions together with a priority ranking.
2. Judge market scope on the three-year regional plan, not on the current order book.
3. Prioritize models with high evidence maturity and spend the limited window on projects that can catch it.
4. Plan backward from December 31, 2027, and evaluate the one-window combined service for projects filed within 2026.
5. When running dual-track parallel, establish unified dossier version control to prevent two contradictory files for one model.

5. Verification checklist

• □ The market scope judgment for every model is complete (Kazakhstan only, or including other member states)
• □ Evidence maturity has been assessed (foreign clinical data, ISO 13485, completeness of the technical file)
• □ A backward plan to the endpoint of December 31, 2027 has been established
• □ The four dispositions (national first, union first, dual-track parallel, defer) have been output
• □ Model priorities are ranked by feasibility multiplied by market value divided by compliance cost
• □ A unified dossier version control mechanism exists for dual-track parallel cases

GRZAN provides registration support in Kazakhstan for medical device manufacturers, importers and authorized representatives, covering route selection, portfolio planning, dossier preparation and post-grant registration maintenance. For assistance with this topic, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.